The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.

[1]  C. Bloomfield,et al.  Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B , 1980, Cancer.

[2]  C. J. Wilcox,et al.  Influence of genetic factors on the susceptibility of cattle to bovine leukemia virus infection. , 1979, European journal of cancer.

[3]  B. Bundy,et al.  Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. , 1979, Cancer treatment reports.

[4]  H. Hansen,et al.  Phase I trial of a new form of an oral administration of VP-16-213. , 1979, Cancer treatment reports.

[5]  L. Baker,et al.  VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary. , 1978, European journal of cancer.

[6]  A. Ferguson,et al.  Chemotherapy of small cell carcinoma of the lung with V. P. 16–213 , 1978, Cancer.

[7]  J. Ingle,et al.  VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. , 1978, Cancer treatment reports.

[8]  C. Coltman,et al.  Evaluation of VP-16-213 in malignant lymphoma and melanoma. , 1978, Cancer treatment reports.

[9]  M. Mastrangelo,et al.  Phase II trial of VM-26 in patients with metastatic malignant melanoma. , 1978, Cancer treatment reports.

[10]  H. Senn,et al.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. , 1978, Cancer treatment reports.

[11]  G. Rivera,et al.  Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma. , 1977, Cancer treatment reports.

[12]  R. Maurer,et al.  Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. , 1977, Cancer research.

[13]  F. Hirsch,et al.  Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP‐16‐213 (NSC 141540, 4′‐demethylepipodophyllotoxin 9‐(4,6‐0‐ethylidene‐β‐D‐glucopyranoside) , 1977, Cancer.

[14]  D. V. Von Hoff,et al.  VM 26 and VP 16–213: A comparative analysis , 1977, Cancer.

[15]  J. Minna,et al.  Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma. , 1977, Cancer treatment reports.

[16]  J. Loike,et al.  Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. , 1976, Biochemistry.

[17]  B. Barlogie,et al.  Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. , 1976, Cancer treatment reports.

[18]  K. Brunner,et al.  Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules. , 1976, Cancer treatment reports.

[19]  H. Hansen,et al.  PHASE I clinical trial of an oral solution of VP-16-213. , 1976, Cancer treatment reports.

[20]  J. Rubin,et al.  VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer. , 1976, Cancer treatment reports.

[21]  Donaldson Mh,et al.  Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia. , 1976 .

[22]  I. Smith,et al.  VP 16-213 in acute myelogenous leukaemia , 1976, Postgraduate medical journal.

[23]  I. Strøyer,et al.  Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease. , 1975, Cancer chemotherapy reports.

[24]  V. Alder,et al.  Pyogenic cocci in infantile eczema throughout one year. , 1975, British medical journal.

[25]  H. Senn,et al.  Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors. , 1975, Cancer chemotherapy reports.

[26]  J. Van Dyk,et al.  A clinical trial of the oral form of 4′‐demethyl‐epipodophyllotoxin‐β‐D ethylidene glucoside (NSC 141540) VP 16–213 , 1975 .

[27]  J. Misset,et al.  Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas , 1974, Cancer.

[28]  H. Senn,et al.  Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis. , 1974, European journal of cancer.

[29]  N. Nissen,et al.  Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213). , 1972, Cancer chemotherapy reports.

[30]  N. Nissen,et al.  Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. , 1972, Cancer chemotherapy reports.

[31]  H. Walton,et al.  Typical Medical Students , 1964, Canadian Medical Association journal.

[32]  C. Begg,et al.  VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474). , 1979, Cancer treatment reports.

[33]  J. Herson,et al.  Nonresponsiveness of brain tumors to VM-26 therapy in children. , 1979, Cancer treatment reports.

[34]  R. Fisher,et al.  Activity of the Epipodophyllotoxin VP‐16 in the Treatment of Combination Chemotherapy‐Resistant Non‐Hodgkin Lymphoma , 1978, American journal of hematology.

[35]  L. Allen,et al.  Mechanism of cellular transport of two epipodophyllotoxin glucopyranoside derivatives, vm-26 (vm) and vp-16 (vp). Abstr. , 1977 .